武汉艾必赛生物有限公司推荐Anti-Human PD-1 Reference Antibody (Daxokafusp Alfa, RUO) ,精品抗体

链接：https://www.abinscience.cn/product/34/56277.html

名称：Anti-Human PD-1 Reference Antibody (Daxokafusp Alfa, RUO)

货号：HS870606

种属反应性：Human

应用：ELISA, FACS, Functional assay

宿主：Human

同种型：IgG1, kappa-IL15RA-IL15

克隆类型：Monoclonal

靶标：CD279, PD1, PDCD1, Programmed cell death protein 1, Protein PD-1, hPD-1

内毒素水平：< 10 EU/mg

纯度：>95% as determined by SDS-PAGE.

纯化方式：Protein A/G purified from cell culture supernatant.

Accession号：Q15116

状态：Liquid

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

产品介绍：Anti-Human PD-1 Reference Antibody (Daxokafusp Alfa, RUO)｜HS870606 是艾必赛生物（abinScience）推出的人源化单克隆参照抗体（人 IgG4-kappa），靶向人程序性死亡蛋白 1（PD-1/CD279），可作为 PD-1/PD-L1 免疫检查点研究的阳性/药物参照质控工具。该抗体在哺乳动物细胞中表达，糖基化更接近天然构象，经 Protein A/G 纯化，纯度 >95%（SDS-PAGE），以液体形式保存在 0.01M PBS, pH 7.4 中；频繁使用 2–8°C，长期建议 -20°C 至 -80°C（自收货日起 ≤12 个月）避反复冻融。（RUO，仅限科研/非临床用途）

PD-1（CD279） 是 B7/CD28 家族的Ⅰ型跨膜抑制性受体，主要表达于活化的 T 细胞、B 细胞、NK 细胞及树突状细胞等，通过与配体 PD-L1（CD274）或 PD-L2（CD273） 结合传递负向共刺激信号，抑制 T 细胞活化与细胞因子分泌，是维持外周耐受、防止自身免疫的关键“刹车”。肿瘤微环境广泛利用 PD-1/PD-L1 轴实现免疫逃逸——肿瘤细胞高表达 PD-L1 与 T 细胞表面的 PD-1 结合，使肿瘤浸润 T 细胞功能耗竭；因此，阻断 PD-1 通路的单抗（如 Pembrolizumab、Nivolumab 等）已成为肿瘤免疫治疗最成功的药物类别之一，在黑色素瘤、非小细胞肺癌、霍奇金淋巴瘤等多种恶性肿瘤中实现持久应答。Daxokafusp Alfa 作为 PD-1 靶点的临床阶段参考分子，其配套参照抗体 HS870606 适用于 ELISA、FACS、体外功能 assay 及体内研究，可用于 PK/PD 研究、方法开发及抗药抗体（ADA）检测等科研场景。

产品购买联系方式：027-87433958/17302791434

邮箱：info@abinscience.com

参考文献：

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. PMID: 26997480

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). PMID: 40627813

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. PMID: 31682550

The blockade of immune checkpoints in cancer immunotherapy. PMID: 22437870

CTLA-4: a moving target in immunotherapy. PMID: 29118008

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. PMID: 32200442

The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. PMID: 37022474

Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. PMID: 39089739

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. PMID: 29442540

The PD-1/PD-L pathway in rheumatic diseases. PMID: 32334916

Cutaneous adverse events caused by immune checkpoint inhibitors. PMID: 34332798

The PD-1:PD-L1 axis in Inflammatory Arthritis. PMID: 33423684

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. PMID: 38268921

Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contr?le immuns. PMID: 30595202

PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives. PMID: 39014460

Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy. PMID: 39941004

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. PMID: 32173382

Characteristic differences in the abundance of tumor-infiltrating lymphocytes and intratumoral developing T cells in thymoma, with special reference to PD-1 expression. PMID: 37060363

Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. PMID: 39187481

Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. PMID: 36587500

PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. PMID: 28122590

Revealing anti-PD-1 resistance mechanisms in HCC: A path towards novel combination immunotherapies. PMID: 35513202

PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. PMID: 34572736

PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. PMID: 32354698

PD-1 and PD-L1 Expression in Indian Women with Breast Cancer. PMID: 35059588

Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy. PMID: 37403095

Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches. PMID: 38986869

[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer]. PMID: 31196371

PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy? PMID: 29296515

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis. PMID: 36465399

Inflammatory myopathy associated with PD-1 inhibitors. PMID: 30862448

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. PMID: 26325035

Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. PMID: 32442903

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends. PMID: 40820303

BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. PMID: 40577656

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。